2269 — WuXi Biologics (Cayman) Balance Sheet
0.000.00%
- HK$144.73bn
- HK$136.95bn
- CNY21.79bn
Annual balance sheet for WuXi Biologics (Cayman), fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 11,126 | 8,714 | 11,243 | 10,710 | 15,733 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 4,768 | 6,038 | 6,713 | 6,374 | 9,007 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 19,530 | 18,470 | 21,198 | 23,573 | 28,135 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 19,756 | 25,916 | 29,939 | 28,435 | 29,754 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 44,033 | 49,564 | 56,576 | 56,977 | 63,697 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 8,256 | 9,319 | 7,636 | 8,621 | 8,308 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 11,754 | 14,517 | 16,244 | 15,158 | 16,448 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 32,279 | 35,047 | 40,332 | 41,819 | 47,249 |
| Total Liabilities & Shareholders' Equity | 44,033 | 49,564 | 56,576 | 56,977 | 63,697 |
| Total Common Shares Outstanding |